BioTek Announces New Applications and Business Development Manager in Canada
News Feb 28, 2011
"Dr. Amirmansour has a unique set of skills, creating cutting-edge business development programs, with an extensive background in life science and drug discovery applications," notes Gary Barush, BioTek's Director of Marketing & Sales. "Additionally, his strong academic background will resonate with our research-based microplate technologies."
Prior to joining BioTek, Dr. Amirmansour held various positions at PerkinElmer, Inc., most recently as Product Line Leader and Sr. Technology Specialist. Following the receipt of his doctorate in clinical pharmacology, Dr. Amirmansour worked as a post-doctoral research fellow at The William Harvey Research Institute, National Heart & Lung Institute and Harefield Heart Science Centre under the supervision of Nobel Laureates, Professors Sir John Vane and Sir Magdy Yacoub.
We congratulate Dr. Amirmansour as he assumes his new responsibilities.
BioTek Instruments, Inc., headquartered in Winooski, VT, USA, is a worldwide leader in the design, manufacture, and sale of microplate instrumentation and software. BioTek instrumentation is used to aid in the advancement of life science research, facilitate the drug discovery process and to enable cost-effective quantification of disease relevant molecules in the clinic.
Study Reveals How MRSA Infection Compromises Lymphatic FunctionNews
Infections of the skin or other soft tissues with the hard-to-treat MRSA bacteria appear to permanently compromise the lymphatic system, which is crucial to immune system function. Investigators describe how MRSA infection impairs the ability of lymphatic vessels to pump lymphatic fluid to lymph nodes in mouse models, which may contribute to the frequent recurrences of MRSA infection experienced by patients.
Possible Biomarker to Identify Who Would Benefit from ImmunotherapyNews
While immunotherapy has made a big impact on cancer treatment, the fact remains that only about a quarter of patients respond to these treatments. In a new study, researchers examined tissue samples from melanoma and ovarian cancer patients treated with immunotherapies and found a link between the percentage of antigen-presenting cells expressing PD-L1 and an objective clinical response to treatment.READ MORE